Zur Rose Group including Medpex/Apotal 1,751.9 1,568.7 11.7% Zur Rose Group including Medpex/Apotal, in local currency 14.4% Zur Rose Group 1,476.9 1,355.5 8.9% Zur Rose Group, in local currency 11.4% Markets Germany including Medpex/Apotal 1,096.2 976.0 12.3% Germany including Medpex/Apotal, in local currency 16.5% Germany 821.2 762.8 7.7% Germany, in local currency 11.7% Switzerland 593.1 553.7 7.1% Rest of Europe 66.4 39.7 67.3% Europe, in local currency 73.5% Business models B2C including Medpex/Apotal 1,236.2 1,106.2 11.7% B2C 961.1 893.1 7.6% Professional Services 453.1 422.8 7.2% Marketplace 66.4 39.7 67.3% Revenue, in CHF million (unaudited) 1.10.-31.12.2020 1.10.-31.12.2019 Change Zur Rose Group including Medpex/Apotal 506.7 412.0 23.0% Zur Rose Group including Medpex/Apotal, in local currency 23.6% Zur Rose Group 410.4 355.2 15.5% Zur Rose Group, in local currency 15.9% Markets Germany including Medpex/Apotal 330.9 256.3 29.1% Germany including Medpex/Apotal, in local currency 29.8% Germany 234.6 199.5 17.6% Germany, in local currency 18.0% Switzerland 158.2 143.9 10.0% Rest of Europe 18.8 11.8 59.5% Europe, in local currency 60.3% Business models B2C including Medpex/Apotal 369.4 291.9 26.5% B2C 273.0 235.1 16.1% Professional Services 119.7 107.7 11.2% Marketplace 18.8 11.8 59.5%
The elimination of revenue between markets and business models is not shown separately.
Investors and analyst contact Christoph Herrmann, Head of Investor Relations Email: ir@zurrose.com, phone: +41 58 810 11 49
Media contact Lisa Lüthi, Head of Group Communications Email: media@zurrose.com, phone: +41 52 724 08 14
Agenda 18 March 2021 2020 Full-Year Results 20 April 2021 First Quarter Trading Update 29 April 2021 Annual General Meeting 19 August 2021 Half-Year Results 21 October 2021 Q3 Trading Update
Zur Rose Group
The Swiss Zur Rose Group is Europe's largest e-commerce pharmacy and one of the leading medical wholesalers in Switzerland. It also operates the leading marketplace in southern Europe for consumer health, beauty and personal care products commonly sold in pharmacies. The company is internationally present with strong brands, including Germany's best-known pharmacy brand DocMorris. Zur Rose employs more than 1,800 people at sites in Switzerland, Germany, the Netherlands, Spain and France. In 2020 it generated revenue of CHF 1,752 million (including Medpex and Apotal) and currently has 10.5 million active customers in core European markets.
With its business model, the Zur Rose Group offers high-quality, safe and cost-effective pharmaceutical care. It is also characterized by the continuous further development of digital services in the field of drug management using AI-supported applications and new technology. Zur Rose is furthermore actively driving ahead its positioning as a comprehensive provider of healthcare services. By creating a digital healthcare platform - the Zur Rose ecosystem - it networks products and digital services from qualified providers. The contribution made by Zur Rose will be to take these offerings to customers and patients and to make a relevant selection. The aim is to provide people with a seamless accompaniment and empower them to manage their own health optimally using products and digital solutions.
The shares of Zur Rose Group AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker ROSE). For further information please see zurrosegroup.com.
^[1] As the separation of the mail-order business has not yet been completed, Medpex and Apotal had only a minor impact on the consolidated revenue of the Zur Rose Group. ^[2] Customers supplied by the Zur Rose Group, either directly or through its partners. -----------------------------------------------------------------------------------------------------------------------
End of Media Release -----------------------------------------------------------------------------------------------------------------------
Language: English Company: Zur Rose Group AG Walzmühlestrasse 60 8500 Frauenfeld Switzerland Phone: +41 52 724 08 14 Internet: www.zurrosegroup.com ISIN: CH0042615283 Listed: SIX Swiss Exchange EQS News ID: 1162093 End of News EQS Group News Service =----------
(MORE TO FOLLOW) Dow Jones Newswires
January 21, 2021 01:02 ET (06:02 GMT)